Literature DB >> 23857568

A novel c.776_777insA mutation in CLN1 leads to infantile neuronal ceroid lipofuscinosis.

Jake N Miller1, David A Pearce.   

Abstract

The neuronal ceroid lipofuscinoses are the most common autosomal recessive neurodegenerative disorders in children, with a worldwide incidence of 1 in 100,000 live births. Multiple clinical variants are caused by more than 400 mutations in at least 14 different genes. These progressive genetic disorders primarily manifest in the central nervous system because of an extensive loss of neurons, specifically in the cerebral and cerebellar cortices. Patients with mutations in CLN1, which encodes palmitoyl-protein thioesterase 1 (PPT1), primarily manifest with infantile neuronal ceroid lipofuscinosis (Haltia-Santavuori disease). Affected children usually present between 1 and 2 years of age and typically die by 8 to 13 years of age. We describe a patient with infantile neuronal ceroid lipofuscinosis with a novel c.776_777insA mutation in CLN1. This insertion induces a frameshift and a premature stop codon late within the CLN1 messenger RNA (mRNA) transcript which is likely recognized by nonsense-mediated translation repression, decreasing PPT1 abundance.

Entities:  

Keywords:  Batten disease; CLN1; infantile neuronal ceroid lipofuscinosis; palmitoyl-protein thioesterase 1

Mesh:

Substances:

Year:  2013        PMID: 23857568     DOI: 10.1177/0883073813494267

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

1.  A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.

Authors:  Feng Yu; Xiao-Min Liu; Yin-He Chen; Sheng-Quan Zhang; Kai Wang
Journal:  Neurol Sci       Date:  2015-06-02       Impact factor: 3.307

Review 2.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

3.  The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy.

Authors:  Jake N Miller; Attila D Kovács; David A Pearce
Journal:  Hum Mol Genet       Date:  2014-09-08       Impact factor: 6.150

4.  Tissue-specific variation in nonsense mutant transcript level and drug-induced read-through efficiency in the Cln1(R151X) mouse model of INCL.

Authors:  Vaughn Thada; Jake N Miller; Attila D Kovács; David A Pearce
Journal:  J Cell Mol Med       Date:  2015-12-09       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.